- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals Inc stock price live, this page displays NASDAQ TARS stock exchange data. View the TARS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Tarsus Pharmaceuticals Inc real time stock price chart below.
What Is the Tarsus Pharmaceuticals Inc Stock Price Today?
The Tarsus Pharmaceuticals Inc stock price today is 58.85.
What Is the Stock Symbol for Tarsus Pharmaceuticals Inc?
The stock symbol for Tarsus Pharmaceuticals Inc is ""TARS.""
What Stock Exchange Does Tarsus Pharmaceuticals Inc Trade On?
Tarsus Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Tarsus Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Tarsus Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TARS quote. (ISIN: US87650L1035)
What Is the Tarsus Pharmaceuticals Inc Stock Price Today?
The Tarsus Pharmaceuticals Inc stock price today is 58.85.
What Is the Stock Symbol for Tarsus Pharmaceuticals Inc?
The stock symbol for Tarsus Pharmaceuticals Inc is ""TARS.""
What Stock Exchange Does Tarsus Pharmaceuticals Inc Trade On?
Tarsus Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Tarsus Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Tarsus Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TARS quote. (ISIN: US87650L1035)
Fair Value
An estimate of a Tarsus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
56.04
58.95
52 wk Range
25.82
58.95
TARS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
1/2
Fair Value
An estimate of a Tarsus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
56.0458.95
52 wk Range
25.8258.95
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TARS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Tarsus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
76.00
Upside
+29.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Tarsus Pharmaceuticals Inc Company Profile
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals Inc SWOT Analysis
XDEMVY's Market Impact | Explore how Tarsus Pharmaceuticals' flagship eye care treatment XDEMVY is driving exceptional revenue growth and expanding its prescriber base among ECPs |
Financial Trajectory | Delve into Tarsus' impressive 948% revenue surge and the challenges of balancing growth investments with the path to profitability |
Strategic Expansion | Learn about Tarsus' ventures into Meibomian Gland Dysfunction treatments and ongoing clinical trials to diversify its product portfolio |
Analyst Perspectives | Discover varied analyst views on Tarsus' potential, with price targets ranging from $45 to $85, reflecting both optimism and caution about future prospects |
Tarsus Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- Q2 revenue beat at $102.7M vs $95.68M forecast; EPS missed at -$0.48 vs -$0.38 expected
- Stock surged 16.52% after-hours to $47.95 despite EPS miss, driven by strong revenue and guidance
- Xtendi product shows robust growth with 94,000 bottles shipped; 93% gross margin maintained
- Company projects Q3 dispensing of 95,000-100,000 bottles; explores global expansion opportunities
- Management confident in exceeding $1B peak sales projection; retreatment rates expected to reach 20% annually
Last Updated: 21/08/2025, 12:26
Read Full TranscriptCompare TARS to Peers and Sector
Metrics to compare | TARS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTARSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −27.0x | −1.5x | −0.5x | |
PEG Ratio | −0.55 | 0.12 | 0.00 | |
Price/Book | 7.5x | 1.7x | 2.6x | |
Price / LTM Sales | 8.4x | 1.8x | 3.3x | |
Upside (Analyst Target) | 41.3% | 110.5% | 38.7% | |
Fair Value Upside | Unlock | 9.8% | 5.0% | Unlock |
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 76.00
(+29.14% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
-0.48 / -0.38
Revenue / Forecast
102.70M / 95.68M
People Also Watch
FAQ
What Stock Exchange Does Tarsus Trade On?
Tarsus is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Tarsus?
The stock symbol for Tarsus is "TARS."
What Is the Tarsus Market Cap?
As of today, Tarsus market cap is 2.48B.
What Is Tarsus's Earnings Per Share (TTM)?
The Tarsus EPS (TTM) is -2.31.
When Is the Next Tarsus Earnings Date?
Tarsus will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is TARS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Tarsus Stock Split?
Tarsus has split 0 times.
How Many Employees Does Tarsus Have?
Tarsus has 323 employees.
What is the current trading status of Tarsus (TARS)?
As of 27 Aug 2025, Tarsus (TARS) is trading at a price of 58.85, with a previous close of 56.61. The stock has fluctuated within a day range of 56.04 to 58.95, while its 52-week range spans from 25.82 to 58.95.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.